Oncology nurses and ancillary support personnel who work in oncology settings are at risk for exposure to antineoplastic drugs in their workplaces. A review of the literature reveals issues of environmental contamination and personal exposure. Although the United States has no formal regulations regarding hazardous drugs, including cytotoxic agents, guidelines have been published and are readily available to improve workplace safety. Oncology healthcare workers must be aware of the serious nature of antineoplastic drug exposure and the avenues available to initiate a simple, highly effective, problem-solving process called SOLVE® to make medical workplaces safer.

At a Glance

- Handling antineoplastic agents incorrectly increases risk for personal and environmental exposure.
- Compliance with organizational guidelines in the proper handling of antineoplastic agents should be assessed routinely.
- SOLVE® is a very effective and positive process that can be used by organizations to measure outcomes regarding compliance in the handling of antineoplastic agents.

The likelihood that a worker will experience adverse effects from hazardous drugs increases with the frequency of exposure, and the risk of adverse effects rises significantly with a lack of proper work practices.

Currently, neither NIOSH, the Occupational Safety and Health Administration (OSHA), nor the American Conference of Governmental Industrial Hygienists has established recommended exposure limits (RELs) or threshold limit values for workplace safety in regard to hazardous drugs. RELs refer to concentrations of chemical substances and represent conditions under

Jackie Gambrell, RN, BSN, OCN®, is an oncology nurse navigator at the Oncology Multidisciplinary Center in the Cancer Treatment Center at Greenville Hospital Systems in South Carolina, and Susan Moore, RN, MSN, ANP, AOCN®, is an oncology nurse practitioner at Rush University Medical Center in Chicago, IL. The authors were participants in the 2005 CJON® Writing Mentorship Program, which was underwritten through an unrestricted educational grant from Amgen Inc. No significant financial relationship to disclose. (Submitted October 2005. Accepted for publication December 10, 2005.)

Digital Object Identifier: 10.1188/06.CJON.473-477